Monte Rosa Therapeutics Inc
GLUE
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.28B
Close$
$19.06
8.4% upside
Current Fair Value
8.4% upsideUndervalued by 8.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.28 Billion |
|---|---|
| Enterprise Value | $1.20 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.46 |
| Beta | 1.62 |
| Outstanding Shares | 65,543,723 |
Return
| Return on Equity | -24.91% |
|---|---|
| Return on Assets | -17.65% |
| Return on Invested Capital | -22.60% |
Valuation & Multiples
| P/E Ratio | -9.94 |
|---|---|
| PEG | 5.1 |
| Price to Sales | - |
| Price to Book Ratio | 2.51 |
| Enterprise Value to Revenue | 27.84 |
| Enterprise Value to EBIT | -7.95 |
| Enterprise Value to Net Income | -10 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 0.14 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-0.38
Average shareholder expectationRevenue Estimate
$11.41 M
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.37
Average shareholder expectationRevenue Estimate
$12.91 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.3668▼ 53.23% |
|---|---|
| Total Calls | 208,300▼ 25.18% |
| Total Puts | 76,400▼ 69.48% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 104.66%▲ 26.40% |
|---|---|
| Total Invested | $1.43B▲ 41.45% |
| Investors Holding | 194▲ 27.00% |
ESG Score
No data
About Monte Rosa Therapeutics Inc
60 employees